Baxter International has appointed John Rogers as executive vice president and chief financial officer, the medical products company announced on 19 August 2026. Rogers takes up the role on 1 October 2026.
Rogers, 58, joins Baxter from Smith and Nephew, the London listed medical technology group, where he has served as chief financial officer since 2024 after joining as chief financial officer designate in 2023. His career spans some of the largest listed companies in the United Kingdom. He was chief financial officer of the advertising group WPP from 2020 to 2023, and before that held senior roles at the retailer J Sainsbury, including chief executive of Sainsbury's Argos from 2016 to 2019 and group chief financial officer from 2010 to 2016.
Baxter International, headquartered in Deerfield, Illinois, supplies a broad portfolio of hospital and critical care products, medication delivery systems and connected care technologies to healthcare providers around the world.
The appointment brings to Baxter a finance leader with deep experience of complex, multinational operations and of guiding large organisations through restructuring and portfolio change. That profile is directly relevant to the task ahead. Baxter has spent the past two years reshaping itself, including the divestiture of its kidney care business, and the finance function sits at the centre of that transition.
Baxter's search for a permanent chief financial officer comes at a demanding moment for the medical products sector. Manufacturers are contending with cost inflation, supply chain fragility exposed by recent disruptions, and pressure on margins from hospital customers managing their own budgets. A chief financial officer with a record of disciplined capital allocation and cost management signals that the board intends to prioritise financial stability and cash generation as it completes its reshaping.
The decision to recruit externally, rather than promote from within, is notable. It suggests the board wanted a fresh perspective and a proven public company finance chief to help reset expectations with investors after a period of transformation. Rogers's experience across retail, advertising and now medical technology gives him a broad view of how different industries manage margin and growth, though he will need to build familiarity with the specific regulatory and reimbursement dynamics of healthcare.
For investors, the appointment adds a measure of stability to Baxter's leadership team as it moves past the most disruptive phase of its restructuring. The effective date of 1 October gives the company a clear handover window, and the seniority of Rogers's prior roles lends credibility to Baxter's message that it is entering a more settled period focused on execution and returns.
